Cargando…

Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report

Background: Therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely manner as per evidence-based clinical guidelines, is an important barrier limiting optimal care in the elderly. Therefore, overcoming therapeutic inertia is the core challenge when dealing with geria...

Descripción completa

Detalles Bibliográficos
Autores principales: Dardano, Angela, Daniele, Giuseppe, Penno, Giuseppe, Miccoli, Roberto, Del Prato, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292593/
https://www.ncbi.nlm.nih.gov/pubmed/34307425
http://dx.doi.org/10.3389/fmed.2021.699477
_version_ 1783724856570806272
author Dardano, Angela
Daniele, Giuseppe
Penno, Giuseppe
Miccoli, Roberto
Del Prato, Stefano
author_facet Dardano, Angela
Daniele, Giuseppe
Penno, Giuseppe
Miccoli, Roberto
Del Prato, Stefano
author_sort Dardano, Angela
collection PubMed
description Background: Therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely manner as per evidence-based clinical guidelines, is an important barrier limiting optimal care in the elderly. Therefore, overcoming therapeutic inertia is the core challenge when dealing with geriatric patients. Case Description: The patient was an 80-year-old man that attended our Outpatient Lipid Clinic (Pisa University Hospital) because of persistent high LDL cholesterol (LDLc) levels in a setting of a statin contraindication. He underwent five percutaneous coronary angioplasties with drug-eluting stents. In 2014, upon starting treatment with rosuvastatin for LDLc level of 7.59 mmol/L, the patient was admitted to the Emergency Room for a presumptive diagnosis of rhabdomyolysis (creatine kinase 6685 U/L) secondary to statin. Patient developed acute kidney injury treated with dialysis. After resolution, he was discharged with ezetimibe (10 mg daily). This treatment however failed to effectively reduce LDLc levels that ranged between 5.9 and 6.6 mmol/L for the ensuing 4-years. In 2018, at the time of our evaluation, in consideration of the age, we performed a comprehensive geriatric assessment that showed good functional and mental status supporting a reliable treatment with a proprotein convertase subtilisin–kexin type 9 inhibitor. Therefore, alirocumab was prescribed as add-on to ezetimibe. At 24-month follow-up, the geriatric assessment showed no significant changes, and alirocumab was well-tolerated. LDLc was 82% lower as compared to baseline values (from 6.6 to 1.2 mmol/L). Conclusions: This report describes a case of therapeutic inertia despite a very high-risk profile. It is also instrumental in highlightening that appropriate intensification of therapy in an elderly patient at high cardiovascular risk, by means of a patient-centered approach, may allow reaching therapeutic targets and overcoming the condition of therapeutic inertia.
format Online
Article
Text
id pubmed-8292593
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82925932021-07-22 Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report Dardano, Angela Daniele, Giuseppe Penno, Giuseppe Miccoli, Roberto Del Prato, Stefano Front Med (Lausanne) Medicine Background: Therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely manner as per evidence-based clinical guidelines, is an important barrier limiting optimal care in the elderly. Therefore, overcoming therapeutic inertia is the core challenge when dealing with geriatric patients. Case Description: The patient was an 80-year-old man that attended our Outpatient Lipid Clinic (Pisa University Hospital) because of persistent high LDL cholesterol (LDLc) levels in a setting of a statin contraindication. He underwent five percutaneous coronary angioplasties with drug-eluting stents. In 2014, upon starting treatment with rosuvastatin for LDLc level of 7.59 mmol/L, the patient was admitted to the Emergency Room for a presumptive diagnosis of rhabdomyolysis (creatine kinase 6685 U/L) secondary to statin. Patient developed acute kidney injury treated with dialysis. After resolution, he was discharged with ezetimibe (10 mg daily). This treatment however failed to effectively reduce LDLc levels that ranged between 5.9 and 6.6 mmol/L for the ensuing 4-years. In 2018, at the time of our evaluation, in consideration of the age, we performed a comprehensive geriatric assessment that showed good functional and mental status supporting a reliable treatment with a proprotein convertase subtilisin–kexin type 9 inhibitor. Therefore, alirocumab was prescribed as add-on to ezetimibe. At 24-month follow-up, the geriatric assessment showed no significant changes, and alirocumab was well-tolerated. LDLc was 82% lower as compared to baseline values (from 6.6 to 1.2 mmol/L). Conclusions: This report describes a case of therapeutic inertia despite a very high-risk profile. It is also instrumental in highlightening that appropriate intensification of therapy in an elderly patient at high cardiovascular risk, by means of a patient-centered approach, may allow reaching therapeutic targets and overcoming the condition of therapeutic inertia. Frontiers Media S.A. 2021-07-07 /pmc/articles/PMC8292593/ /pubmed/34307425 http://dx.doi.org/10.3389/fmed.2021.699477 Text en Copyright © 2021 Dardano, Daniele, Penno, Miccoli and Del Prato. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Dardano, Angela
Daniele, Giuseppe
Penno, Giuseppe
Miccoli, Roberto
Del Prato, Stefano
Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
title Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
title_full Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
title_fullStr Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
title_full_unstemmed Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
title_short Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
title_sort breaking therapeutic inertia with alirocumab in an 80-year-old patient with severe hypercholesterolemia: a case report
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292593/
https://www.ncbi.nlm.nih.gov/pubmed/34307425
http://dx.doi.org/10.3389/fmed.2021.699477
work_keys_str_mv AT dardanoangela breakingtherapeuticinertiawithalirocumabinan80yearoldpatientwithseverehypercholesterolemiaacasereport
AT danielegiuseppe breakingtherapeuticinertiawithalirocumabinan80yearoldpatientwithseverehypercholesterolemiaacasereport
AT pennogiuseppe breakingtherapeuticinertiawithalirocumabinan80yearoldpatientwithseverehypercholesterolemiaacasereport
AT miccoliroberto breakingtherapeuticinertiawithalirocumabinan80yearoldpatientwithseverehypercholesterolemiaacasereport
AT delpratostefano breakingtherapeuticinertiawithalirocumabinan80yearoldpatientwithseverehypercholesterolemiaacasereport